$HRMY
Harmony Biosciences Holdings Inc

2022 Q4 Form 10-Q Financial Statement

#000155837022015726 Filed on November 01, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3
Revenue $128.3M $117.2M
YoY Change 40.67% 45.18%
Cost Of Revenue $26.89M $22.96M
YoY Change 50.9% 57.21%
Gross Profit $101.4M $94.25M
YoY Change 38.19% 42.52%
Gross Profit Margin 79.05% 80.41%
Selling, General & Admin $37.76M $41.80M
YoY Change 1.19% 25.38%
% of Gross Profit 37.23% 44.35%
Research & Development $10.09M $40.55M
YoY Change 35.44% 245.41%
% of Gross Profit 9.95% 43.02%
Depreciation & Amortization $6.068M $6.063M
YoY Change 27.48% 29.77%
% of Gross Profit 5.98% 6.43%
Operating Expenses $53.81M $82.35M
YoY Change 20.21% 82.69%
Operating Profit $47.61M $11.90M
YoY Change 66.3% -43.47%
Interest Expense -$3.583M -$3.990M
YoY Change -14.43% -26.51%
% of Operating Profit -7.53% -33.53%
Other Income/Expense, Net $73.00K $56.00K
YoY Change 135.48%
Pretax Income $44.10M $7.967M
YoY Change 80.2% -175.72%
Income Tax -$4.406M -$79.98M
% Of Pretax Income -9.99% -1003.84%
Net Earnings $48.51M $87.94M
YoY Change 113.56% -1014.17%
Net Earnings / Revenue 37.81% 75.03%
Basic Earnings Per Share $1.48
Diluted Earnings Per Share $0.79 $1.44
COMMON SHARES
Basic Shares Outstanding 59.32M 59.16M
Diluted Shares Outstanding 61.21M

Balance Sheet

Concept 2022 Q4 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $323.1M $307.8M
YoY Change 37.9% 62.23%
Cash & Equivalents $243.8M $261.3M
Short-Term Investments $79.33M $46.42M
Other Short-Term Assets $8.786M $4.108M
YoY Change 173.03% 29.06%
Inventory $4.297M $3.900M
Prepaid Expenses $9.347M $11.25M
Receivables $54.74M $55.07M
Other Receivables $0.00 $0.00
Total Short-Term Assets $400.3M $382.1M
YoY Change 40.73% 58.74%
LONG-TERM ASSETS
Property, Plant & Equipment $573.0K $680.0K
YoY Change -30.12% -27.43%
Goodwill
YoY Change
Intangibles $161.0M $166.9M
YoY Change 11.84% 12.35%
Long-Term Investments $22.57M $8.280M
YoY Change
Other Assets $2.798M $3.079M
YoY Change -20.4% 1925.66%
Total Long-Term Assets $273.6M $261.4M
YoY Change 83.61% 73.79%
TOTAL ASSETS
Total Short-Term Assets $400.3M $382.1M
Total Long-Term Assets $273.6M $261.4M
Total Assets $673.9M $643.5M
YoY Change 55.47% 64.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.786M $10.05M
YoY Change 278.22% 140.46%
Accrued Expenses $59.94M $85.61M
YoY Change 48.93% 150.14%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $2.000M $2.000M
YoY Change 0.0% 0.0%
Total Short-Term Liabilities $78.88M $107.4M
YoY Change 46.69% 125.43%
LONG-TERM LIABILITIES
Long-Term Debt $189.6M $189.7M
YoY Change -0.18% -0.18%
Other Long-Term Liabilities $2.501M $2.498M
YoY Change -21.28% 80.75%
Total Long-Term Liabilities $192.1M $192.2M
YoY Change -0.52% 0.4%
TOTAL LIABILITIES
Total Short-Term Liabilities $78.88M $107.4M
Total Long-Term Liabilities $192.1M $192.2M
Total Liabilities $271.0M $299.6M
YoY Change 9.76% 25.31%
SHAREHOLDERS EQUITY
Retained Earnings -$272.1M -$320.6M
YoY Change -40.01% -32.68%
Common Stock $675.1M $664.7M
YoY Change 5.47% 5.79%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $402.8M $343.9M
YoY Change
Total Liabilities & Shareholders Equity $673.9M $643.5M
YoY Change 55.47% 64.53%

Cashflow Statement

Concept 2022 Q4 2022 Q3
OPERATING ACTIVITIES
Net Income $48.51M $87.94M
YoY Change 113.56% -1014.17%
Depreciation, Depletion And Amortization $6.068M $6.063M
YoY Change 27.48% 29.77%
Cash From Operating Activities $26.68M $55.21M
YoY Change -28.92% 81.45%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$86.00K
YoY Change -7.53%
Acquisitions
YoY Change
Other Investing Activities -$46.89M -$32.36M
YoY Change
Cash From Investing Activities -$46.89M -$32.45M
YoY Change 34787.1%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.658M 2.050M
YoY Change -62.42% -754.95%
NET CHANGE
Cash From Operating Activities 26.68M 55.21M
Cash From Investing Activities -46.89M -32.45M
Cash From Financing Activities 2.658M 2.050M
Net Change In Cash -17.56M 24.81M
YoY Change -139.37% -17.35%
FREE CASH FLOW
Cash From Operating Activities $26.68M $55.21M
Capital Expenditures $0.00 -$86.00K
Free Cash Flow $26.68M $55.29M
YoY Change -28.92% 81.18%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
27034000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-38927000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
1623000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
43171000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
8545000
CY2022Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
1802000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-151000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
16000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
117788000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
61024000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
55637000
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58825769
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
96000
CY2022Q3 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
CY2021Q3 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
872000
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
CY2022Q3 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
dei Entity Central Index Key
EntityCentralIndexKey
0001802665
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
2000000
CY2022Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1371000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-15000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1360000
CY2021Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
CY2021Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
59304408
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57188101
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-532000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
347000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
982000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4479000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3715000
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q3 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
CY2022Q3 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent
CY2022Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent
CY2022Q3 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39450
dei Entity Registrant Name
EntityRegistrantName
HARMONY BIOSCIENCES HOLDINGS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-2279923
dei Entity Address Address Line1
EntityAddressAddressLine1
630 W.
dei Entity Address Address Line2
EntityAddressAddressLine2
Germantown Pike
dei Entity Address Address Line3
EntityAddressAddressLine3
Suite 215
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
9048000
dei Entity Address City Or Town
EntityAddressCityOrTown
Plymouth Meeting
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19462
dei City Area Code
CityAreaCode
484
dei Local Phone Number
LocalPhoneNumber
539-9800
dei Security12b Title
Security12bTitle
Common Stock, par value $0.00001 value per share
dei Trading Symbol
TradingSymbol
HRMY
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
59317554
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
261343000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
234309000
CY2022Q3 us-gaap Short Term Investments
ShortTermInvestments
46420000
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
55065000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
34843000
CY2022Q3 us-gaap Inventory Net
InventoryNet
3900000
CY2021Q4 us-gaap Inventory Net
InventoryNet
4432000
CY2022Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
11246000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
7637000
CY2022Q3 us-gaap Other Assets Current
OtherAssetsCurrent
4108000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
3218000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
382082000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
284439000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
680000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
820000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
750000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
750000
CY2022Q3 us-gaap Long Term Investments
LongTermInvestments
8280000
CY2022Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
166914000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
143919000
CY2022Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
81679000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3079000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3515000
CY2022Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
261382000
CY2021Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
149004000
CY2022Q3 us-gaap Assets
Assets
643464000
CY2021Q4 us-gaap Assets
Assets
433443000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
10049000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1001000
CY2022Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
8331000
CY2021Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
9165000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
85606000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
40249000
CY2022Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
2000000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
107357000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
53775000
CY2022Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
189725000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
189984000
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2498000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3177000
CY2022Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
192223000
CY2021Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
193161000
CY2022Q3 us-gaap Liabilities
Liabilities
299580000
CY2021Q4 us-gaap Liabilities
Liabilities
246936000
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
59304408
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58825769
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
1000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
664700000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
640104000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-178000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-320639000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-453598000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
343884000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
186507000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
643464000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
433443000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
117206000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
80732000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
309547000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
214227000
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
22959000
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
14604000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
56596000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
37701000
CY2022Q3 us-gaap Gross Profit
GrossProfit
94247000
CY2021Q3 us-gaap Gross Profit
GrossProfit
66128000
us-gaap Gross Profit
GrossProfit
252951000
us-gaap Gross Profit
GrossProfit
176526000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
40548000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11739000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
60794000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22916000
CY2022Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
20467000
CY2021Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
16480000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
58210000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
49009000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
21331000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16856000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
61374000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
45704000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
82346000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
45075000
us-gaap Operating Expenses
OperatingExpenses
180378000
us-gaap Operating Expenses
OperatingExpenses
117629000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
11901000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
21053000
us-gaap Operating Income Loss
OperatingIncomeLoss
72573000
us-gaap Operating Income Loss
OperatingIncomeLoss
58897000
CY2021Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-26146000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-26146000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
56000
CY2022Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-3990000
CY2021Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-5429000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-12086000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-19783000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
7967000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10522000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
60583000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
12953000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-79976000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-902000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-72376000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1070000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
87943000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-9620000
us-gaap Net Income Loss
NetIncomeLoss
132959000
us-gaap Net Income Loss
NetIncomeLoss
11883000
CY2022Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-149000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-178000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
87794000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9620000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
132781000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
11883000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.48
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.25
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.21
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.44
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.18
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.20
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59234720
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57722163
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59070063
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
61207625
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57722163
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60921482
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58776158
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
186507000
us-gaap Net Income Loss
NetIncomeLoss
132959000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-178000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
408000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5275000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
18913000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
343884000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
246533000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
87943000
CY2022Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-149000
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
408000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2143000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7006000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
343884000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
97180000
us-gaap Net Income Loss
NetIncomeLoss
11883000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
29700000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1794000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11461000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
152018000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
126551000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-9620000
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
29700000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1134000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4253000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
152018000
us-gaap Profit Loss
ProfitLoss
132959000
us-gaap Profit Loss
ProfitLoss
11883000
us-gaap Depreciation
Depreciation
312000
us-gaap Depreciation
Depreciation
299000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
17005000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
13781000
us-gaap Share Based Compensation
ShareBasedCompensation
18913000
us-gaap Share Based Compensation
ShareBasedCompensation
11461000
hrmy Stock Appreciation Rights Market Adjustment
StockAppreciationRightsMarketAdjustment
321000
hrmy Stock Appreciation Rights Market Adjustment
StockAppreciationRightsMarketAdjustment
261000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1241000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1820000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-81679000
us-gaap Investment Income Interest
InvestmentIncomeInterest
225000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-26146000
us-gaap Other Noncash Expense
OtherNoncashExpense
1042000
us-gaap Other Noncash Expense
OtherNoncashExpense
916000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
20222000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
11030000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
172000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
298000
hrmy Cash Paid For Milestones
CashPaidForMilestones
40000000
hrmy Cash Paid For Milestones
CashPaidForMilestones
100000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-94937000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-100298000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
408000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
30000000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
300000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
200000000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
9147000
us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
200000000
hrmy Payments Of Extinguishment Of Debt Exit Fees
PaymentsOfExtinguishmentOfDebtExitFees
22000000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1500000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5275000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1794000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4183000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
235059000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
229381000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
262093000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
190454000
us-gaap Interest Paid Net
InterestPaidNet
11334000
us-gaap Interest Paid Net
InterestPaidNet
15997000
CY2020Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
410239
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-320639000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-453598000
CY2022Q3 us-gaap Investments And Cash
InvestmentsAndCash
316043000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;"><b style="font-style:normal;font-weight:bold;">Use of Estimates</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosures in the unaudited condensed consolidated financial statements, including the notes thereto, and elsewhere in this report. Actual results may differ significantly from estimates, which include rebates due pursuant to commercial and government contracts, accrued research and development expenses, stock-based compensation expense and income taxes. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Uncertainties related to the magnitude and duration of COVID-19, the extent to which it will impact our future financial results, worldwide macroeconomic conditions including interest rates, employment rates, consumer spending and health insurance coverage, the speed of the anticipated recovery and governmental and business reactions to the pandemic have increased the complexity of developing estimates and assumptions used in the preparation of the unaudited condensed consolidated financial statements, including the carrying amounts of long-lived assets, and the intangible asset. Actual results may differ significantly from our estimates as a result of COVID-19.</p>
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
261343000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
234309000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
750000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
750000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
262093000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
235059000
CY2022Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
166914000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;"><b style="font-style:normal;font-weight:bold;">Concentrations of Risk</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Substantially all of the Company’s cash and money market funds are held in two financial institutions. Due to their size, the Company believes these financial institutions represent minimal credit risk. Deposits may exceed the amount of insurance provided on such deposits by the Federal Deposit Insurance Corporation for U.S. institutions. The Company has not experienced any losses on its deposits of cash and cash equivalents. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is also subject to credit risk from its trade receivables related to its product sales. The Company extends credit to specialty pharmaceutical distribution companies within the United States. Customer creditworthiness is monitored and collateral is not required. Historically, the Company has not experienced credit losses on its accounts receivable. The Company monitors its exposure within accounts receivable and would record a reserve against uncollectible accounts receivable if necessary As of September 30, 2022, three customers accounted for 100% of gross accounts receivable; Caremark LLC (“CVS Caremark”), which accounted for 47% of gross accounts receivable; Accredo Health Group, Inc. (“Accredo”), which accounted for 30% of gross accounts receivable; and, PANTHERx Specialty Pharmacy LLC (“Pantherx”, which accounted for 23% of gross accounts receivable. As of December 31, 2021, three customers accounted for 100% of gross accounts receivable; Accredo, which accounted for 40% of gross accounts receivable; Pantherx, which accounted for 31% of gross accounts receivable; and CVS Caremark, which accounted for 29% of gross accounts receivable.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the nine months ended September 30, 2022, three customers accounted for 100% of gross product revenues; CVS Caremark accounted for 40% of gross product revenues; Pantherx accounted for 30% of gross product revenues; and Accredo accounted for 30% of gross product revenues. For the nine months ended September 30, 2021, three customers accounted for 100% of gross product revenues; CVS Caremark accounted for 36% of gross product revenues; Pantherx accounted for 36% of gross product revenues; and Accredo accounted for 28% of gross product revenues.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company depends on a single source supplier for each of its product and active pharmaceutical ingredient.</p>
hrmy Concentrations Of Risk Number Of Financial Institutions
ConcentrationsOfRiskNumberOfFinancialInstitutions
2
CY2022Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
235213000
CY2021Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
156782000
CY2022Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
605000
CY2021Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
986000
CY2021Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1787000
CY2022Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
2137000
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
2108000
CY2022Q3 us-gaap Inventory Gross
InventoryGross
4544000
CY2021Q4 us-gaap Inventory Gross
InventoryGross
4881000
CY2022Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
644000
CY2021Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
449000
CY2022Q3 us-gaap Inventory Net
InventoryNet
3900000
CY2021Q4 us-gaap Inventory Net
InventoryNet
4432000
CY2022Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5962000
CY2021Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
4573000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
17005000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
13781000
CY2022Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
5961000
CY2022Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
23845000
CY2022Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
23845000
CY2022Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
23845000
CY2022Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
23845000
CY2022Q3 hrmy Finite Lived Intangible Asset Expected Amortization After Year Four
FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
65573000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
301000
CY2022Q3 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
215000000
CY2021Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
175000000
CY2022Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
48086000
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
31081000
CY2022Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
166914000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
143919000
CY2022Q3 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
20944000
CY2021Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
16396000
CY2022Q3 hrmy Accrued Rebates And Other Sales Deductions Current
AccruedRebatesAndOtherSalesDeductionsCurrent
25214000
CY2021Q4 hrmy Accrued Rebates And Other Sales Deductions Current
AccruedRebatesAndOtherSalesDeductionsCurrent
17141000
CY2022Q3 us-gaap Interest Payable Current
InterestPayableCurrent
3041000
CY2021Q4 us-gaap Interest Payable Current
InterestPayableCurrent
2125000
CY2022Q3 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
2326000
CY2021Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
1983000
CY2022Q3 hrmy Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
1852000
CY2021Q4 hrmy Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
658000
CY2022Q3 hrmy Accrued Professional Fees Consulting And Other Services
AccruedProfessionalFeesConsultingAndOtherServices
1229000
CY2021Q4 hrmy Accrued Professional Fees Consulting And Other Services
AccruedProfessionalFeesConsultingAndOtherServices
1645000
CY2022Q3 hrmy Accrued Licensing Fee Current
AccruedLicensingFeeCurrent
30000000
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1000000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
85606000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
40249000
CY2022Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
198000000
CY2021Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
199500000
CY2022Q3 hrmy Unamortized Debt Discount Associated With Exit Fee Debt Financing Costs And Discount With Warrant Financing
UnamortizedDebtDiscountAssociatedWithExitFeeDebtFinancingCostsAndDiscountWithWarrantFinancing
6275000
CY2021Q4 hrmy Unamortized Debt Discount Associated With Exit Fee Debt Financing Costs And Discount With Warrant Financing
UnamortizedDebtDiscountAssociatedWithExitFeeDebtFinancingCostsAndDiscountWithWarrantFinancing
7516000
CY2022Q3 us-gaap Long Term Debt
LongTermDebt
191725000
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
191984000
CY2022Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
2000000
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
2000000
CY2022Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
189725000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
189984000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3298000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1598000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1527000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1384000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2233000
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
500000
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
2000000
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
20000000
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
20000000
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
155500000
CY2022Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
198000000
CY2022Q3 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
4513000
CY2021Q3 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
5030000
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
12110000
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
18122000
CY2022Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
418000
CY2021Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
459000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1241000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1820000
CY2022Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
4931000
CY2021Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
5489000
us-gaap Interest Expense Debt
InterestExpenseDebt
13351000
us-gaap Interest Expense Debt
InterestExpenseDebt
19942000
CY2018Q2 hrmy Operating Lease Office Space
OperatingLeaseOfficeSpace
15000
CY2020Q4 hrmy Operating Lease Office Space
OperatingLeaseOfficeSpace
13000
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
us-gaap Lessee Operating Lease Existence Of Option To Terminate
LesseeOperatingLeaseExistenceOfOptionToTerminate
true
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
378000
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
359000
us-gaap Operating Lease Cost
OperatingLeaseCost
1155000
us-gaap Operating Lease Cost
OperatingLeaseCost
916000
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y10M24D
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.038
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2658000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
2982000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
3760000
us-gaap Operating Lease Payments
OperatingLeasePayments
1297000
us-gaap Operating Lease Payments
OperatingLeasePayments
833000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
485000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3365000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
419000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1679000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
958000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
34000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3090000
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
108000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
2982000
CY2022Q3 us-gaap Loss Contingency Pending Claims Number
LossContingencyPendingClaimsNumber
0
us-gaap Common Stock Voting Rights
CommonStockVotingRights
one vote for each share
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5716597
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
22.53
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M2D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1533961
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
48.59
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
457145
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
10.72
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
168758
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
31.42
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6624655
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
29.15
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y11M8D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7257
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.7633
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.6000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0199
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0405
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0066
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0144
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6967000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4664000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
19234000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11722000
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
83981000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y1M6D
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
87943000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-9620000
us-gaap Net Income Loss
NetIncomeLoss
132959000
us-gaap Net Income Loss
NetIncomeLoss
11883000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.48
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.25
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.21
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.44
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.18
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.20
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59234720
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57722163
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59070063
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57188101
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
61207625
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57722163
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60921482
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58776158
CY2022Q3 hrmy Securities Outstanding Included In Computation Of Utilizing Treasury Stock Method
SecuritiesOutstandingIncludedInComputationOfUtilizingTreasuryStockMethod
1972905
hrmy Securities Outstanding Included In Computation Of Utilizing Treasury Stock Method
SecuritiesOutstandingIncludedInComputationOfUtilizingTreasuryStockMethod
1851419
hrmy Securities Outstanding Included In Computation Of Utilizing Treasury Stock Method
SecuritiesOutstandingIncludedInComputationOfUtilizingTreasuryStockMethod
1588057
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
96366000
hrmy Tax Benefit Release Of Valuation Allowance
TaxBenefitReleaseOfValuationAllowance
74474000
CY2022Q3 hrmy Tax Benefit Release Of Valuation Allowance
TaxBenefitReleaseOfValuationAllowance
74474000
hrmy Tax Benefit Deferred Tax Assets Utilized
TaxBenefitDeferredTaxAssetsUtilized
21892000
CY2022Q3 hrmy Tax Benefit Deferred Tax Assets Utilized
TaxBenefitDeferredTaxAssetsUtilized
21892000
CY2022Q3 us-gaap Related Party Transaction Due From To Related Party
RelatedPartyTransactionDueFromToRelatedParty
0
CY2021Q4 us-gaap Related Party Transaction Due From To Related Party
RelatedPartyTransactionDueFromToRelatedParty
0

Files In Submission

Name View Source Status
0001558370-22-015726-index-headers.html Edgar Link pending
0001558370-22-015726-index.html Edgar Link pending
0001558370-22-015726.txt Edgar Link pending
0001558370-22-015726-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
hrmy-20220930.xsd Edgar Link pending
hrmy-20220930x10q.htm Edgar Link pending
hrmy-20220930xex10d1.htm Edgar Link pending
hrmy-20220930xex10d2.htm Edgar Link pending
hrmy-20220930xex10d2001.jpg Edgar Link pending
hrmy-20220930xex10d2003.jpg Edgar Link pending
hrmy-20220930xex10d2015.jpg Edgar Link pending
hrmy-20220930xex31d1.htm Edgar Link pending
hrmy-20220930xex31d2.htm Edgar Link pending
hrmy-20220930xex32d1.htm Edgar Link pending
hrmy-20220930xex32d2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
hrmy-20220930_def.xml Edgar Link unprocessable
hrmy-20220930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
hrmy-20220930_cal.xml Edgar Link unprocessable
hrmy-20220930x10q_htm.xml Edgar Link completed
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
hrmy-20220930_lab.xml Edgar Link unprocessable